Uncategorized
STAT+: Lilly’s obesity pill enters the oral GLP-1 game, Novo responds
The FDA yesterday approved Eli Lilly’s weight loss pill, orforglipron. The agency is also facing renewed scrutiny over transparency gaps related to advisory committee conflicts, and its “breakthrough” label for devices is drifting toward more ambitious — but not necessarily better-validated — AI tools.
Meanwhile, Insilico Medicine is pitching AI drug discovery as a sort of asset factory rather than a means to guaranteed approval ends.
Trump may not be done with import tariffs on drugs
The Trump administration has prepared an order that would impose a 100% tariff on some imports of patented medications and their active ingredients, according to a draft obtained by STAT reporter Daniel Payne. The tariffs could be announced as soon as today, according to a person familiar with the matter, although it’s also possible timelines and plans could shift.
The FDA yesterday approved Eli Lilly’s weight loss pill, orforglipron. The agency is also facing renewed scrutiny over transparency gaps related to advisory committee conflicts, and its “breakthrough” label for devices is drifting toward more ambitious — but not necessarily better-validated — AI tools.
Meanwhile, Insilico Medicine is pitching AI drug discovery as a sort of asset factory rather than a means to guaranteed approval ends.
Trump may not be done with import tariffs on drugs
The Trump administration has prepared an order that would impose a 100% tariff on some imports of patented medications and their active ingredients, according to a draft obtained by STAT reporter Daniel Payne. The tariffs could be announced as soon as today, according to a person familiar with the matter, although it’s also possible timelines and plans could shift.
Uncategorized
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.” Read More
Uncategorized
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday.
The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached. It also highlights both the therapeutic and commercial promise of antibody-drug conjugates, the next-generation chemotherapy treatments that the privately held Tubulis is developing.
Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion. The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
In a move that will grow its oncology pipeline, Gilead Sciences is spending more than $3 billion to buy the German biotech Tubulis, the companies said Tuesday.
The deal includes an upfront payment of $3.15 billion and up to $1.85 billion more if certain milestones are reached. It also highlights both the therapeutic and commercial promise of antibody-drug conjugates, the next-generation chemotherapy treatments that the privately held Tubulis is developing.
Gilead’s latest move comes just months after it said it would acquire Arcellx in a deal worth $7.8 billion. The two companies had already been working together on a multiple myeloma CAR-T therapy that could be approved later this year. Gilead last month also announced that it was buying Ouro Therapeutics, which is focused on drugs for autoimmune disease, for up to $2.18 billion.
In its third acquisition of 2026, Gilead is spending $3.15 billion upfront to snag a next-generation antibody-drug conjugate platform from German startup Tubulis.
The California biopharma could pay out another $1.85 billion down the road …
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
STAT+: Gilead to buy cancer biotech Tubulis for more than $3 billion
Gilead continues dealmaking streak with $3.15B Tubulis buy for ADCs
BioNTech to shutter Singapore HQ after ‘comprehensive review’
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
STAT+: Merck’s experimental HIV prevention pill could be made for less than $5 a year, researchers say
Illinois’ financial crisis could bring the state to a halt
The final 6 ‘Game of Thrones’ episodes might feel like a full season
New Season 8 Walking Dead trailer flashes forward in time
Mod turns ‘Counter-Strike’ into a ‘Tekken’ clone with fighting chickens
Meet Superman’s grandfather in new trailer for Krypton
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years agoThese ’90s fashion trends are making a comeback in 2017
-
Contributors9 years ago
The final 6 ‘Game of Thrones’ episodes might feel like a full season
-
Uncategorized9 years ago
According to Dior Couture, this taboo fashion accessory is back
-
Uncategorized9 years ago
The old and New Edition cast comes together to perform
-
Uncategorized9 years ago
Phillies’ Aaron Altherr makes mind-boggling barehanded play
-
Uncategorized9 years ago
Uber and Lyft are finally available in all of New York State
-
Uncategorized9 years ago
Disney’s live-action Aladdin finally finds its stars
-
Uncategorized9 years ago
Steph Curry finally got the contract he deserves from the Warriors